Companion animal postoperative pain management therapeutics market is expected to grow at a significant CAGR during the forecast period. The demand for postoperative pain relievers is increasing as the number of pet surgical operations, particularly orthopaedic and dental surgery, increases. The rising frequency of periodontal disease is likely to drive the demand for dental procedures. According to the AMA research, dog clinic visits climbed by 6% from 2014 to 2017, owing to an increase in dental disorders. Revenue growth is expected to be aided by rising companion animal ownership. The market is likely to be fueled by increased acceptance of NSAIDs coupled with the restricted use of opioids to reduce postoperative pain. The demand for companion pain-relieving medications is expected to rise significantly owing to rising concerns among pet owners and decreased use of off-label human painkillers. The unmet demand for long-acting local anaesthetics in small animals is motivating the pharmaceutical sector to create these medications.
For instance, in situ Biologics', AniGel SR demonstrated 72-hour efficacy in pre-clinical research for postoperative pain management. The medicine is awaiting approval from the US Food and Drug Administration (FDA), which would likely raise market revenue in the future years. The Animal Cancer Foundation estimates that there were 65 million dogs and 32 million cats in the US in 2017. The market for companion animal postoperative pain management pharmaceuticals is being fueled by an increase in the number of veterinary facilities and pet clinics. According to a survey by the American Veterinary Medical Association (AVMA), private practise for small animals increased by 14% in the United States in 2018. Opioids' use as postoperative pain medications is being hampered by strict rules on their use in people and animals. Around 40% of veterinarians in the US prescribed opioids for perioperative therapy in animals in 2014. These factors are projected to hinder the growth of the market.
To Request a Sample of our Report on Companion Animal Postoperative Pain Management Therapeutics Market: https://www.omrglobal.com/request-sample/companion-animal-postoperative-pain-management-therapeutics-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape:Zoetis Inc., Merck Animal Health, and Ceva Santé Animale, among Others.
Companion Animal Postoperative Pain Management Therapeutics Market Report Segmentation
By Product
- NSAIDs
- Anesthetics
- Others
By Animal Type
- Canine
- Feline
A full Report of Companion Animal Postoperative Pain Management Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/companion-animal-postoperative-pain-management-therapeutics-market
Companion Animal Postoperative Pain Management Therapeutics Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404